UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
PXMD holding history
Kuvatris Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
PXMD overviewAll 13F holders of PXMDFull Q2 2026 holdings
- Shares (Q1 2024)
- 0
- Sold out in Q1 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 5
- Since Q3 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2024 | 0 | $0 | 0.0% | −491−100.0% | Sold out | Holders |
| Q4 2023 | 491 | $372 | <0.1% | −607−55.3% | Reduced | Holders |
| Q3 2023 | 1,098 | $314 | <0.1% | +1,098 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −17,735−100.0% | Sold out | Holders |
| Q1 2023 | 17,735 | $33.9K | <0.1% | −15,669−46.9% | Reduced | Holders |
| Q4 2022 | 33,404 | $67.8K | <0.1% | +27,198+438.3% | Added | Holders |
| Q3 2022 | 6,206 | $15.0K | <0.1% | +6,206 | New | Holders |